New hepatitis C therapy
Two new drugs, VictrelisTM (boceprevir) and IncivekTM (telaprevir) were recently introduced as new treatment therapies for hepatitis C. Both drugs offer new hope to patients who are infected with this virus. Studies submitted to the Food and Drug Administration (FDA) for approval of these drugs demonstrated that when taken correctly, Victrelis or Incivek results in an average cure rate of 78 percent.1 This is significant considering hepatitis C is the most common infection of the liver worldwide, and affects an estimated 130 to 210 million people.2
How Cigna is helping
Adherence is crucial in the success of these new complex hepatitis therapies. We are here to help your patients achieveoptimal clinical outcomes by working with physicians and by offering the following pharmacy and clinical services that can help ensure patients arereceiving and taking their medications appropriately:
Cigna Home Delivery Pharmacy
Cigna Home Delivery Pharmacy is available to your patients for their prescription needs. Standard services include 24/7 availability of a licensed pharmacists, convenient home delivery or other preferred location at no additional cost and automatic refill reminders.
Clinical program support
Our clinical programs are available to support your patients with adherence and managing side effects, and to educate them about chronic conditions including hepatitis C:
Victrelis and Incivek are covered under the Pharmacy benefit as non-preferred drugs and require prior authorization. These drugs can only be authorized when used in conjunction with Pegylated Interferon and Ribavirin to achieve the most favorable results. The revised prior authorization form is available on the Cigna for Health Care Professionals website (CignaforHCP.com > Pharmacy > Forms).
1 FDA Advisory Committee Briefing Document. FDA Antiviral Drugs Advisory Committee Meeting: Boceprevir Capsules (NDA 202-258), March 29, 2011. FDA Advisory Committee Briefing Document. Vertex Pharmaceuticals Antiviral Drugs Advisory Committee Meeting: Telaprevir (NDA 201-917), April 28, 2011.
2Craxi A, Pawlotsky J, Wedemyer H, et al. European Association for the Study of the Liver: EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology 2011 Vol. 55 p. 245-264.
|Table of Contents|
|Home | Print Version | Legal Disclaimer | ©2011 CIGNA||PREVIOUS PAGE | NEXT PAGE|